Edgar Filing: CTI BIOPHARMA CORP - Form 4

CTI BIOPHARMA	CORP							
Form 4 October 24, 2016								
	OMB APPROVAL							
FORM 4	FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							
See Instruction	Filed pursuant to Section 17(a) of th	OF CHANGES I SEC Section 16(a) of Public Utility H	N BENEFICIAI URITIES the Securities Ex	Number: January 31, Expires: 2005 Estimated average burden hours per response 0.5				
1(b).								
(Print or Type Response	es)							
1. Name and Address of LOVE RICHARD		Symbol	and Ticker or Trading	Issuer	5. Relationship of Reporting Person(s) to Issuer			
(Last) (Fi	rst) (Middle)	3. Date of Earlies	Ľ	(Chec	(Check all applicable)			
3101 WESTERN 2	, , , , , , , , , , , , , , , , , , ,	(Month/Day/Year		below)	X Officer (give title Other (specify			
(St	reet)	4. If Amendment Filed(Month/Day/	-	Applicable Line) _X_ Form filed by C	_X_ Form filed by One Reporting Person			
SEATTLE, WA 98	8121			Form filed by M Person	fore than One Ro	eporting		
(City) (St	ate) (Zip)	Table I - No	n-Derivative Securit	ties Acquired, Disposed of	, or Beneficia	lly Owned		
	any	on Date, if Transac Code Day/Year) (Instr. 8	4. Securities tionAcquired (A) or Disposed of (D)) (Instr. 3, 4 and 5) (A) or V Amount (D) H	Securities F Beneficially (1 Owned (1	. Ownership Form: Direct D) or Indirect I) Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Report on a	separate line for each	class of securities be	neficially owned dire	ectly or indirectly.				
			Persons who information required to r	o respond to the collec contained in this form respond unless the forr urrently valid OMB con	are not n	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: CTI BIOPHARMA CORP - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8)	Acquired (<i>A</i> Disposed o (Instr. 3, 4, 5)	f (D)				
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Employee Stock Option (Right to Buy)	\$ 0.4087	10/20/2016		A	500,000		<u>(1)</u>	10/20/2026	Common Stock	500,00
Employee Stock Option (Right to Buy)	\$ 0.4087	10/20/2016		A	500,000		(2)	10/20/2026	Common Stock	500,00

Reporting Owners

Reporting Owner Name / Address								
	Director	10% Owner	Officer	Other				
LOVE RICHARD L 3101 WESTERN AVENUE, SUITE 600 SEATTLE, WA 98121	3101 WESTERN AVENUE, SUITE 600 X			Interim CEO and President				
Signatures								
/s/ Louis A. Bianco, attorney-in-fact for Richard L. Love			0/24/2016					
<u>**</u> Signature of Reporting Person		Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option is scheduled to vest in six monthly installments following the grant date, subject to the reporting person's continued employment with the issuer through the applicable vesting date.

The option is scheduled to vest in six monthly installments following the grant date, subject to the reporting person's continued(2) employment with the issuer through the applicable vesting date, and provided that a specified performance objective is achieved prior to October 2, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.